Alnylam files its third RNAi drug lumasiran in rare kidney diseaseGene-silencing specialist Alnylam has completed filings in the US and EU for lumasiran, which aced a phase 3 Share XAlnylam files its third RNAi drug lumasiran in rare kidney diseasehttps://pharmaphorum.com/news/alnylam-files-its-third-rnai-drug-lumasiran-in-rare-kidney-disease/
Novo bolsters R&D pipeline with RNAi therapies from DicernaNovo Nordisk has further bolstered its liver disease R&D pipeline, signing a deal with US biotech Dicerna to Share XNovo bolsters R&D pipeline with RNAi therapies from Dicernahttps://pharmaphorum.com/news/novo-bolsters-rd-pipeline-with-rnai-therapies-from-dicerna/
Roche swoops on Dicerna’s gene-silencing hepatitis B drugDicerna Pharma has enticed another big pharma to partner its RNA interference platform, attracting a $200 million upfront Share XRoche swoops on Dicerna’s gene-silencing hepatitis B drughttps://pharmaphorum.com/news/roche-swoops-on-dicernas-gene-silencing-hepatitis-b-drug/
Dicerna agrees another gene-silencing deal, this time with LillyEli Lilly has agreed a broad collaboration with Dicerna, sealing the deal with a $100 million equity stake Share XDicerna agrees another gene-silencing deal, this time with Lillyhttps://pharmaphorum.com/news/dicerna-agrees-another-gene-silencing-deal-this-time-with-lilly/
Alexion joins with Dicerna to develop RNAi therapies for complement diseasesAlexion has announced a collaboration with Dicerna Pharmaceuticals to discover and develop RNA interference therapies for diseases caused Share XAlexion joins with Dicerna to develop RNAi therapies for complement diseaseshttps://pharmaphorum.com/news/alexion-joins-with-dicerna-to-develop-rnai-therapies-for-complement-diseases/
